RADICAVA ORS

Peak

edaravone

NDAORALSUSPENSIONPriority Review
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
0/100

Loss of Exclusivity

LOE Date
Nov 12, 2041
191 months away
Patent Expiry
Nov 12, 2041
Exclusivity Expiry
May 12, 2029

Patent Records (5)

Patent #ExpiryTypeUse Code
12285409
Nov 1, 2039
Product
—
11478450
Nov 1, 2039
U-3468
11826352
Nov 1, 2039
Product
—
10987341
Nov 1, 2039
Product
—
11957660
Nov 1, 2039
Product
—
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers